AcquisitionsSep 10, 2026, 06:08 AM
Axogen to Acquire BioCircuit Technologies for $200M; Prices $208.7M Stock Offering
AI Summary
Axogen, Inc. announced a definitive agreement to acquire BioCircuit Technologies, Inc. for $200 million in cash. BioCircuit's flagship product, NerveTape, is the first FDA-approved device for sutureless peripheral nerve repair, which Axogen believes will broaden its addressable market and accelerate adoption. The transaction is expected to close in the fourth quarter of 2026. Concurrently, Axogen priced a public offering of 4,910,000 shares of common stock at $42.50 per share, expecting to raise approximately $208.7 million, with net proceeds intended to fund the acquisition.
Key Highlights
- Axogen to acquire BioCircuit Technologies for $200 million in cash.
- BioCircuit's NerveTape is the first FDA-approved device for sutureless peripheral nerve repair.
- Transaction expected to close in Q4 2026, subject to customary conditions.
- Axogen priced a public offering of 4,910,000 shares of common stock at $42.50 per share, raising approximately $208.7 million.
- Net proceeds from the offering will primarily fund the BioCircuit acquisition.
- Acquisition is expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year post-closing.
Price Impact
More from AXGN